<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647929</url>
  </required_header>
  <id_info>
    <org_study_id>STOP Glaucoma</org_study_id>
    <nct_id>NCT04647929</nct_id>
  </id_info>
  <brief_title>Comparison of Surgical Treatment Options for Primary Congenital and Developmental Glaucomas</brief_title>
  <acronym>STOP-Glaucoma</acronym>
  <official_title>Comparison of Surgical Treatment Options for Primary Congenital and Developmental Glaucomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Newborn and children can be affected by two subgroups of this disease: (1) primary congenital&#xD;
      glaucoma (PCG) or (2) developmental glaucoma (DG). The primary aim of this study is to&#xD;
      compare the Santen PRESERFLO implant to trabeculectomy in PCG and DG patients as second&#xD;
      surgery after failed trabeculotomy or goniotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a chronic, progressive disease, leading to blindness if untreated or&#xD;
      insufficiently treated. It is characterized by a loss of optic nerve fiber and a glaucomatous&#xD;
      optic disc excavation and, a corresponding pattern of visual field loss. Newborn and children&#xD;
      can be affected by two subgroups of this disease: (1) primary congenital glaucoma (PCG) or&#xD;
      (2) developmental glaucoma (DG). PCG and DG are treated surgically, either by goniotomy or by&#xD;
      trabeculotomy as first approach, and not with topical hypotensive medications. Whenever these&#xD;
      procedures have failed, the subsequent surgical procedure is usually trabeculectomy with&#xD;
      Mitomycin C or the implantation of a glaucoma drainage device. However, there is a lack of&#xD;
      evidence regarding the &quot;optimal&quot; surgical approach after failed goniotomy/trabeculotomy.&#xD;
      Optimal treatment in this young group of patients with a long life expectancy is crucial to&#xD;
      prevent blindness, allow them to participate in a &quot;normal&quot; school and work environment, and&#xD;
      to minimize disease burdens for these patients and their families as well as to minimize&#xD;
      costs for society. Consequently, there is the desire to find a procedure with a superior&#xD;
      success rate and even fewer or less severe complications compared to trabeculectomy.&#xD;
      Recently, the Santen PRESERFLO was introduced. The results proved fewer complications and&#xD;
      comparable efficacy to trabeculectomy, according results presented at scientific meetings.&#xD;
      Yet, there are no published studies to compare the both procedures. The primary aim of this&#xD;
      study is to compare the Santen PRESERFLO implant to trabeculectomy in PCG and DG patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Te patients will be randomly assigned in a 1:1 ratio to either (1) Santen PRESERFLO implant (intervention arm) or (2) trabeculectomy (standard therapy) .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy 1</measure>
    <time_frame>at 6months compared to baseline (i.e. preop)</time_frame>
    <description>Change in Goldmann-applanation intraocular pressure (IOP) in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy 2</measure>
    <time_frame>at 6months compared to baseline (i.e. preop)</time_frame>
    <description>Change in the number of drug classes of intraocular pressure (IOP) lowering medications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>within 6 months from surgery</time_frame>
    <description>rate of intraoperative and postoperative complications (safety)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exome Sequencing</measure>
    <time_frame>at baseline</time_frame>
    <description>for known and susprected genes for primary congenital glaucoma or developmental glaucoma as a potential confounder for outcome and rates of complications will be statistically evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Congenital Glaucoma</condition>
  <condition>Developmental Glaucoma</condition>
  <arm_group>
    <arm_group_label>PRESERFLO MicroShunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Santen PRESERFLO MicroShunt</intervention_name>
    <description>the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow</description>
    <arm_group_label>PRESERFLO MicroShunt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minors younger than 18 years of age with a diagnosis of Primary Congenital Glaucoma&#xD;
             (PCG) or Developmental Glaucoma (DG) will be included&#xD;
&#xD;
          -  participants must have had a failed trabeculotomy or goniotomy (once or twice) or one&#xD;
             360° trabeculotomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with eye pathologies other than glaucoma or, who underwent intraocular&#xD;
             surgery within the last 6 months will not be included.&#xD;
&#xD;
          -  patients who will not be willing to proceed with the entire follow-up of 6 months, or&#xD;
             whose legal representative did not sign the informed consent will not be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>- Individuals with eye pathologies other than glaucoma or, who Töteberg-Harms, MD, FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Töteberg-Harms, MD, FEBO</last_name>
    <phone>+41 44 255 1111</phone>
    <email>marc.toeteberg@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susete Vieira</last_name>
    <phone>+41 44 255 1111</phone>
    <email>susete.vieira@usz.ch</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, Arrieta E, Peralta AC, Palmberg P, Parrish RK 2nd, Weber BA, Parel JM. Three-Year Follow-up of a Novel Aqueous Humor MicroShunt. J Glaucoma. 2016 Feb;25(2):e58-65. doi: 10.1097/IJG.0000000000000368.</citation>
    <PMID>26766400</PMID>
  </results_reference>
  <results_reference>
    <citation>Jayaram H, Scawn R, Pooley F, Chiang M, Bunce C, Strouthidis NG, Khaw PT, Papadopoulos M. Long-Term Outcomes of Trabeculectomy Augmented with Mitomycin C Undertaken within the First 2 Years of Life. Ophthalmology. 2015 Nov;122(11):2216-22. doi: 10.1016/j.ophtha.2015.07.028. Epub 2015 Aug 24.</citation>
    <PMID>26315044</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary congenital glaucoma</keyword>
  <keyword>developmental glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hydrophthalmos</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

